The new medicine is an improved follow-on medicine to the Swiss
drugmaker's $7 billion-a-year Rituxan, or MabThera, and Roche is
hoping to switch as many patients as possible to the newer product
before Rituxan faces competition from cheaper copies.
The move endorses a favorable recommendation in May from the
European Medicine Agency's Committee for Medicinal Products for
Human Use (CHMP), which are normally followed by the European
(Reporting By Katharina Bart)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.